

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/972,035	9/972,035 10/04/2001		Daniel Albert Wettstein	1907.03	2866
26698	7590	01/27/2003			
MYRIAD (	GENET.	ICS INC.	EXAMINER		
LEGAL DE 320 WAKA			HILL, MYRON G		
SALT LAKE CITY, UT 84108				ART UNIT	PAPER NUMBER
				1648	3.1
				DATE MAILED: 01/27/2003	()

Please find below and/or attached an Office communication concerning this application or proceeding.

• . •	Application No.	Applicant(s)					
	09/972,035	WETTSTEIN ET AL.					
Office Action Summary	Examiner	Art Unit					
	Myron G. Hill	1648					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on	— · s action is non-final.						
,-		occoution as to the marits is					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  Disposition of Claims							
4)⊠ Claim(s) <u>1- 60</u> is/are pending in the application	1.						
4a) Of the above claim(s) is/are withdraw	vn from consideration.						
5) Claim(s) is/are allowed.							
6)☐ Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) <u>1- 60</u> are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the							
11) The proposed drawing correction filed on		oved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120	arriiror.						
13) Acknowledgment is made of a claim for foreign	priority under 35 H.S.C. & 119/a	)-(d) or (f)					
a) All b) Some * c) None of:	priority under 55 5.5.5. § 115(a	) (d) 01 (i).					
, , ,	s have been received						
<ul> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal I	(PTO-413) Paper No(s) Patent Application (PTO-152)					

Application/Control Number: 09/972,035 Page 2

Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1- 23, and 44- 50 drawn to an isolated protein complex comprising a Tsg101 and an HIV GAG protein, composition, and a host cell comprising them, classified in class 530, subclass 402.
- II. Claim 24, drawn to a method to make an isolated protein complex comprising a Tsg101 and an HIV GAG protein, classified in class 435, subclass 68.1.
  - III. Claim 25, drawn to a protein microarray comprising the isolated protein complex comprising a Tsg101 and an HIV GAG protein, classified in class 436, subclass 518.
  - IV. Claim 26, drawn to a fusion protein comprising a Tsg101 and an HIV GAG protein, classified in class 530, subclass 350.
  - V. Claim 27, drawn to an isolated nucleic acid encoding a fusion protein, classified in class 536, subclass 23.4.
  - VI. Claims 28- 43, drawn to a method to select modulators of an interaction between a first protein and a second, classified in class 436, subclass 501.
  - VII. Claims 51- 53, drawn to a method for providing a compound capable of interfering with an interaction between two proteins using atomic

Application/Control Number: 09/972,035

Art Unit: 1648

coordinates defining three-dimensional structure of the protein complex, classified in class 436, subclass 501.

- VIII. Claims 54- 59, drawn to a method for selecting a compound capable of inhibiting a protein-protein interaction between a Tsg101 and an HIV GAG protein, classified in class 436, subclass 501.
- IX. Claim 60, drawn to an antibody, classified in class 530, subclass 387.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, III, IV, V, and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are drawn to products with different chemical structures that have different functions and uses (antibody, nucleic acid, protein).

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the proteins can be made by chemical synthesis, or recombinantly produced in cells.

Application/Control Number: 09/972,035 Page 4

Art Unit: 1648

Inventions I and VI, VIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in either of the two methods- to determine a modulator of interaction or to determine an inhibitor of interaction.

Inventions VI-VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions they are drawn to different methods that have different starting materials or different steps or different functions of test compound.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, divergent search requirements, and different classifications, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Myron G. Hill whose telephone number is 703-308-4521. The examiner can normally be reached on 9am-6pm Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 703-308-4247. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Myron G. Hill Patent Examiner January 23, 2003

JAMES HOUSEL

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600